表紙:アンチセンスオリゴヌクレオチド (ASO) 治療薬の世界市場:2023-2033年
市場調査レポート
商品コード
1367761

アンチセンスオリゴヌクレオチド (ASO) 治療薬の世界市場:2023-2033年

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 286 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=194.37円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

アンチセンスオリゴヌクレオチド (ASO) 治療薬の世界市場:2023-2033年
出版日: 2023年10月20日
発行: Visiongain Reports Ltd.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアンチセンスオリゴヌクレオチド (ASO) 治療薬の市場規模は、2033年にかけて14.5%のCAGRで成長すると予測されています。

希少疾患治療へのASO治療薬の採用が市場成長を牽引

アンチセンスオリゴヌクレオチド (ASO) の希少遺伝性疾患治療への応用は、この治療アプローチの変革力を示す説得力のある証です。希少疾患は人口における有病率が低いという特徴があるため、従来の医薬品開発においてあまり魅力的ではありませんでした。しかし、ASOはこれらの疾患に苦しむ人々にとって希望の光として登場し、ASOのR&Dには大きな関心と投資が集まっています。

従来の医薬品開発経路では、希少疾患はしばしば大きな障壁に直面します。患者数が少ないため、大規模な臨床試験を実施することが困難であり、このような疾患に対する医薬品開発の財政的な実行可能性にも問題が残ります。ASOは、その精度と適応性により、これらの課題に対処するための新たな可能性を切り開いています。

ASOは、希少疾患の原因となる特定の遺伝子変異や異常を標的とするよう調整することができます。この個別化されたアプローチにより、単なる症状の管理ではなく、症状の根本的な原因に直接対処する治療法の開発が可能になります。このことは、希少疾患の治療状況を一変させる可能性を秘めており、これまで存在しなかった効果的な疾患修飾的治療法の可能性を提供するものです。

当レポートでは、世界のアンチセンスオリゴヌクレオチド (ASO) 治療薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響分析
  • ポーターのファイブフォース分析
  • PEST分析

第4章 アンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析:治療用途別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推計・予測
  • 神経学的障害
  • 遺伝性疾患
  • 腫瘍性疾患
  • 心血管疾患
  • その他

第5章 アンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析:ASO化学別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推計・予測
  • DNAベース
  • RNAベース
  • Gapmer

第6章 アンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析:投与経路別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推計・予測
  • 経肺投与
  • 静脈注射
  • 皮内注射
  • 腹腔内注射
  • 局所投与
  • その他

第7章 アンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析:地域別

  • 主要調査結果
  • 市場規模の推計・予測

第8章 北米のアンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析

第9章 欧州のアンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析

第10章 アジア太平洋地域のアンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析

第11章 ラテンアメリカのアンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析

第12章 中東・アフリカのアンチセンスオリゴヌクレオチド (ASO) 治療薬市場の分析

第13章 企業プロファイル

  • 競合情勢
  • 戦略的展望
  • Biogen
  • Bio-Path Holdings
  • Ionis Pharmaceuticals, Inc.
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • GSK plc
  • Geron Corporation(Geron)
  • Antisense Therapeutics Limited
  • Sterna Biologicals
  • Alector, Inc.
  • Dicerna Pharmaceuticals, Inc.
  • iCo Therapeutics Inc.
  • Roche Holding AG

第14章 総論・提言

  • Visiongainによる総論
  • 市場参入企業への提言
図表

List of Tables

  • Table 1 Antisense Oligonucleotide (ASO) Therapeutics Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
  • Table 2 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 7 Neurological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 8 Genetic Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 9 Oncological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 10 Cardiovascular Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 11 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 12 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 13 DNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 14 RNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 15 Gapmer ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 16 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 17 Pulmonary Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 18 Intravenous Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 19 Intradermal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 20 Intraperitoneal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 21 Topical Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 22 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 23 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 24 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 25 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 26 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 27 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 28 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 29 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 30 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 31 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 32 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 33 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 34 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 35 France Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 36 UK Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 37 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 38 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 39 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 40 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 41 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 42 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 43 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 44 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 45 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 46 China Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 47 India Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 48 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 49 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 50 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 51 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 52 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 53 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 54 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 55 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 56 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 57 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 58 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 59 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 60 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 61 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 62 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 63 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 64 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 65 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 66 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 67 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 68 Strategic Outlook
  • Table 69 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 70 Biogen: Product Benchmarking
  • Table 71 Biogen: Strategic Outlook
  • Table 72 Bio-Path Holdings: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 Bio-Path Holdings: Product Benchmarking
  • Table 74 Bio-Path Holdings: Strategic Outlook
  • Table 75 Ionis Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 Ionis Pharmaceuticals, Inc.: Product Benchmarking
  • Table 77 Ionis Pharmaceuticals, Inc.: Strategic Outlook
  • Table 78 ProQR Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 ProQR Therapeutics: Product Benchmarking
  • Table 80 ProQR Therapeutics: Strategic Outlook
  • Table 81 Sarepta Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Sarepta Therapeutics: Product Benchmarking
  • Table 83 Sarepta Therapeutics: Strategic Outlook
  • Table 84 Alnylam Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Alnylam Pharmaceuticals, Inc.: Product Benchmarking
  • Table 86 Alnylam Pharmaceuticals, Inc.: Strategic Outlook
  • Table 87 Arrowhead Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Arrowhead Pharmaceuticals, Inc.: Product Benchmarking
  • Table 89 Arrowhead Pharmaceuticals, Inc.: Strategic Outlook
  • Table 90 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 GSK plc: Product Benchmarking
  • Table 92 Geron Corporation (Geron): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Geron Corporation (Geron): Product Benchmarking
  • Table 94 Antisense Therapeutics Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Antisense Therapeutics Limited: Product Benchmarking
  • Table 96 Antisense Therapeutics Limited: Strategic Outlook
  • Table 97 Sterna Biologicals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Sterna Biologicals: Product Benchmarking
  • Table 99 Alector, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Alector, Inc.: Product Benchmarking
  • Table 101 Alector, Inc.: Strategic Outlook
  • Table 102 Dicerna Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Dicerna Pharmaceuticals, Inc.: Product Benchmarking
  • Table 104 iCo Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 iCo Therapeutics Inc.: Product Benchmarking
  • Table 106 Roche Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 Roche Holding AG: Product Benchmarking

List of Figures

  • Figure 1 Antisense Oligonucleotide (ASO) Therapeutics Market Segmentation
  • Figure 2 Antisense Oligonucleotide (ASO) Therapeutics Market by Therapeutic Application: Market Attractiveness Index
  • Figure 3 Antisense Oligonucleotide (ASO) Therapeutics Market by ASO Chemistry: Market Attractiveness Index
  • Figure 4 Antisense Oligonucleotide (ASO) Therapeutics Market by Route of Administration: Market Attractiveness Index
  • Figure 5 Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index by Region
  • Figure 6 Antisense Oligonucleotide (ASO) Therapeutics Market: Market Dynamics
  • Figure 7 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 8 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 9 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 10 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 11 Antisense Oligonucleotide (ASO) Therapeutics Market: Porter's Five Forces Analysis
  • Figure 12 Antisense Oligonucleotide (ASO) Therapeutics Market: PEST Analysis
  • Figure 13 Antisense Oligonucleotide (ASO) Therapeutics Market by Therapeutic Application: Market Attractiveness Index
  • Figure 14 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
  • Figure 15 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023, 2028, 2033 (%)
  • Figure 16 Neurological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 17 Neurological Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 18 Genetic Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 19 Genetic Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 20 Oncological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 21 Oncological Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 22 Cardiovascular Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 23 Cardiovascular Diseases Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 24 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 25 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 26 Antisense Oligonucleotide (ASO) Therapeutics Market by ASO Chemistry: Market Attractiveness Index
  • Figure 27 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
  • Figure 28 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023, 2028, 2033 (%)
  • Figure 29 DNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 30 DNA Based ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 31 RNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 32 RNA Based ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 33 Gapmer ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 34 Gapmer ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 35 Antisense Oligonucleotide (ASO) Therapeutics Market by Route of Administration: Market Attractiveness Index
  • Figure 36 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
  • Figure 37 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023, 2028, 2033 (%)
  • Figure 38 Pulmonary Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 39 Pulmonary Delivery Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 40 Intravenous Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 41 Intravenous Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 42 Intradermal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 43 Intradermal Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 44 Intraperitoneal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 45 Intraperitoneal Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 46 Topical Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 47 Topical Delivery Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 48 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 49 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 50 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
  • Figure 51 NASH DNA Based ASO & Therapeutics Market Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 52 NASH DNA Based ASO & Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 53 North America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • Figure 54 North America Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 55 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 56 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 57 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
  • Figure 58 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
  • Figure 59 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
  • Figure 60 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
  • Figure 61 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
  • Figure 62 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 63 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 64 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 65 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • Figure 66 Europe Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 67 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 68 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 69 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
  • Figure 70 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
  • Figure 71 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
  • Figure 72 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
  • Figure 73 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
  • Figure 74 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 75 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 76 France Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 77 UK Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 78 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 79 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 80 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 81 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 82 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • Figure 83 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 84 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 85 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 86 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
  • Figure 87 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
  • Figure 88 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
  • Figure 89 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
  • Figure 90 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
  • Figure 91 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 92 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 93 China Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 94 India Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 95 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 96 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 97 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 98 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 99 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • Figure 100 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 101 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 102 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 103 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
  • Figure 104 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
  • Figure 105 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
  • Figure 106 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
  • Figure 107 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
  • Figure 108 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 109 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 110 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 111 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 112 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 113 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 114 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • Figure 115 MEA Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 116 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 117 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 118 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
  • Figure 119 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
  • Figure 120 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
  • Figure 121 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
  • Figure 122 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
  • Figure 123 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 124 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 125 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 126 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 127 Antisense Oligonucleotide (ASO) Therapeutics Market: Company Share/Ranking, 2022
  • Figure 128 Biogen: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 129 Biogen: Gross Profit, 2017-2022 (US$ Million, AGR %)
  • Figure 130 Biogen: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 131 Ionis Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 132 Ionis Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
  • Figure 133 Ionis Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 134 Sarepta Therapeutics: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 135 Sarepta Therapeutics: Gross Profit, 2017-2022 (US$ Million, AGR %)
  • Figure 136 Sarepta Therapeutics: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 137 Alnylam Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 138 Alnylam Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
  • Figure 139 Alnylam Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 140 Arrowhead Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 141 Arrowhead Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
  • Figure 142 Arrowhead Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 143 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 144 GSK plc: Gross Profit, 2017-2022 (US$ Million, AGR %)
  • Figure 145 GSK plc: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 146 Geron Corporation (Geron): Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 147 Geron Corporation (Geron): R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 148 Antisense Therapeutics Limited: Net Revenue, 2017-2022 (US$ Thousand, AGR%)
  • Figure 149 Antisense Therapeutics Limited: R&D, 2017-2022 (US$ Thousand, AGR%)
  • Figure 150 Roche Holding AG: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 151 Roche Holding AG: R&D, 2017-2022 (US$ Million, AGR %)
目次
Product Code: PHA1292

The global Antisense Oligonucleotide (ASO) Therapeutics market is projected to grow at a CAGR of 14.5% by 2033.

“The Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving Market Growth

The application of antisense oligonucleotides (ASOs) in the treatment of rare genetic disorders is a compelling testament to the transformative power of this therapeutic approach. Rare diseases, often referred to as orphan diseases, are characterized by their low prevalence in the population, making them less attractive for traditional drug development efforts. However, ASOs have emerged as a ray of hope for individuals afflicted by these conditions, driving considerable interest and investment in ASO research and development.

Traditional drug development pathways often face significant hurdles when it comes to rare diseases. The small patient populations make conducting large-scale clinical trials challenging, and the financial viability of developing drugs for such conditions can be questionable. ASOs, with their precision and adaptability, have opened up new possibilities for addressing these challenges.

ASOs can be tailored to target the specific genetic mutations or abnormalities responsible for rare diseases. This personalized approach allows for the development of therapies that directly address the underlying cause of the condition, rather than just managing symptoms. This has the potential to revolutionize the treatment landscape for rare diseases, offering the prospect of effective, disease-modifying treatments where none existed before.

Potential Immunogenicity Response in Some Patients Likely to Challenge Industry Growth

Immunogenicity poses a significant market restraint for the antisense oligonucleotide (ASO) Therapeutics Market. While ASOs hold immense promise in treating a range of diseases, the potential to provoke an immune response in some patients can lead to adverse effects and reduced treatment effectiveness. This immunogenic response may hinder the widespread adoption of ASO therapies and pose challenges in terms of patient safety and regulatory approvals. To mitigate this concern, extensive research and development efforts have been focused on chemical modifications and structural alterations to ASO molecules to reduce their immunogenicity.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Antisense Oligonucleotide (ASO) Therapeutics market evolving?
  • What is driving and restraining the Antisense Oligonucleotide (ASO) Therapeutics market?
  • How will each Antisense Oligonucleotide (ASO) Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each Antisense Oligonucleotide (ASO) Therapeutics submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading Antisense Oligonucleotide (ASO) Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Antisense Oligonucleotide (ASO) Therapeutics projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of Antisense Oligonucleotide (ASO) Therapeutics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Antisense Oligonucleotide (ASO) Therapeutics market?
  • Where is the Antisense Oligonucleotide (ASO) Therapeutics market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Antisense Oligonucleotide (ASO) Therapeutics market today, and over the next 10 years:

  • Our 286-page report provides 107 tables and 151 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Antisense Oligonucleotide (ASO) Therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antisense Oligonucleotide (ASO) Therapeutics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Therapeutic Application

  • Neurological Disorders
  • Genetic Disorders
  • Oncological Disorders
  • Cardiovascular Diseases
  • Others

ASO Chemistry

  • DNA Based ASO
  • RNA Based ASO
  • Gapmer ASO

Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • Alector, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Limited
  • Arrowhead Pharmaceuticals, Inc.
  • Biogen
  • Bio-Path Holdings
  • Dicerna Pharmaceuticals, Inc.
  • Geron Corporation (Geron)
  • GSK plc
  • iCo Therapeutics Inc.
  • Ionis Pharmaceuticals, Inc.
  • ProQR Therapeutics
  • Roche Holding AG
  • Sarepta Therapeutics
  • Sterna Biologicals

Overall world revenue for Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 in terms of value the market will surpass US$6,000.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 ” report help you?

In summary, our 280+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 Market, with forecasts for therapeutic application, ASO chemistry, and route of administration, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 24 key national markets - See forecasts for the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Antisense Oligonucleotide (ASO) Therapeutics Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Developments in the Field of Target Specific Precision Medicine Driving the ASO Therapeutics Market
      • 3.2.1.2 Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving the ASO Therapeutics Market
      • 3.2.1.3 Improved Delivery Systems Helps in Unlocking the Full Potential of ASOs, thereby Boosting the Market
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Off-target Effects Might Act as a Significant Market Restraint in the Development and Adoption of ASO Therapeutics
      • 3.2.2.2 Potential Immunogenicity Response in Some Patients Might Restrain the ASO Therapeutics Market Growth
      • 3.2.2.3 High Cost of Treatment and Manufacturing of ASO Therapeutics Might Impact the Market Growth Negatively
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Novel Approach to Cancer Therapy Might Offer a Promising Market Opportunity to ASO Therapeutics
      • 3.2.3.2 Pipeline Expansion Stands as a Significant Market Opportunity Within the Realm of ASO Therapeutics
      • 3.2.3.3 In the Field of ASO Therapeutics, the Availability of Regulatory Support is a Significant Market Potential
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Therapeutic Application

  • 4.1 Key Findings
  • 4.2 Therapeutic Application Segment: Market Attractiveness Index
  • 4.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
  • 4.4 Neurological Disorders
    • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Genetic Disorders
    • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.6 Oncological Disorders
    • 4.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.6.2 Market Share by Region, 2023 & 2033 (%)
  • 4.7 Cardiovascular Diseases
    • 4.7.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.7.2 Market Share by Region, 2023 & 2033 (%)
  • 4.8 Others
    • 4.8.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.8.2 Market Share by Region, 2023 & 2033 (%)

5 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by ASO Chemistry

  • 5.1 Key Findings
  • 5.2 ASO Chemistry Segment: Market Attractiveness Index
  • 5.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
  • 5.4 DNA Based ASO
    • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 RNA Based ASO
    • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 5.6 Gapmer ASO
    • 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
  • 6.4 Pulmonary Delivery
    • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Intravenous Injections
    • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Intradermal Injections
    • 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)
  • 6.7 Intraperitoneal Injections
    • 6.7.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.7.2 Market Share by Region, 2023 & 2033 (%)
  • 6.8 Topical Delivery
    • 6.8.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.8.2 Market Share by Region, 2023 & 2033 (%)
  • 6.9 Others
    • 6.9.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.9.2 Market Share by Region, 2023 & 2033 (%)

7 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

  • 8.1 Key Findings
  • 8.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • 8.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market .by Country, 2023, 2028 & 2033 (US$ Million)
  • 8.4 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
  • 8.5 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
  • 8.6 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
  • 8.7 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
  • 8.8 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 8.9 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

9 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • 9.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 9.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
  • 9.5 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
  • 9.6 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
  • 9.7 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
  • 9.8 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 9.9 France Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 9.10 UK Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 9.11 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 9.12 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 9.13 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 9.14 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

10 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • 10.3 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 10.4 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
  • 10.6 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
  • 10.7 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
  • 10.8 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 10.9 China Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 10.10 India Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 10.11 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 10.12 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 10.13 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 10.14 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

11 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • 11.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market .by Country, 2023, 2028 & 2033 (US$ Million)
  • 11.4 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
  • 11.5 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
  • 11.6 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
  • 11.7 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
  • 11.8 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 11.9 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 11.10 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 11.11 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 11.12 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

12 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
  • 12.3 MEA Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 12.4 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
  • 12.5 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
  • 12.6 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
  • 12.7 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
  • 12.8 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 12.9 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
  • 12.10 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2022
  • 13.2 Strategic Outlook
  • 13.3 Biogen
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2017-2022
      • 13.3.3.2 Gross Profit, 2017-2022
      • 13.3.3.3 R&D, 2017-2022
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Bio-Path Holdings
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Product Benchmarking
    • 13.4.4 Strategic Outlook
  • 13.5 Ionis Pharmaceuticals, Inc.
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2017-2022
      • 13.5.3.2 Gross Profit, 2017-2022
      • 13.5.3.3 R&D, 2017-2022
    • 13.5.4 Product Benchmarking
    • 13.5.5 Strategic Outlook
  • 13.6 ProQR Therapeutics
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Product Benchmarking
    • 13.6.4 Strategic Outlook
  • 13.7 Sarepta Therapeutics
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2017-2022
      • 13.7.3.2 Gross Profit, 2017-2022
      • 13.7.3.3 R&D, 2017-2022
    • 13.7.4 Product Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 Alnylam Pharmaceuticals, Inc.
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Financial Analysis
      • 13.8.3.1 Net Revenue, 2017-2022
      • 13.8.3.2 Gross Profit, 2017-2022
      • 13.8.3.3 R&D, 2017-2022
    • 13.8.4 Product Benchmarking
    • 13.8.5 Strategic Outlook
  • 13.9 Arrowhead Pharmaceuticals, Inc.
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Financial Analysis
      • 13.9.3.1 Net Revenue, 2017-2022
      • 13.9.3.2 Gross Profit, 2017-2022
      • 13.9.3.3 R&D, 2017-2022
    • 13.9.4 Product Benchmarking
    • 13.9.5 Strategic Outlook
  • 13.10 GSK plc
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2017-2022
      • 13.10.3.2 Gross Profit, 2017-2022
      • 13.10.3.3 R&D, 2017-2022
    • 13.10.4 Product Benchmarking
  • 13.11 Geron Corporation (Geron)
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2017-2022
      • 13.11.3.2 R&D, 2017-2022
    • 13.11.4 Product Benchmarking
  • 13.12 Antisense Therapeutics Limited
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Financial Analysis
      • 13.12.3.1 Net Revenue, 2017-2022
      • 13.12.3.2 R&D, 2017-2022
    • 13.12.4 Product Benchmarking
    • 13.12.5 Strategic Outlook
  • 13.13 Sterna Biologicals
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Product Benchmarking
  • 13.14 Alector, Inc.
    • 13.14.1 Company Snapshot
    • 13.14.2 Company Overview
    • 13.14.3 Product Benchmarking
    • 13.14.4 Strategic Outlook
  • 13.15 Dicerna Pharmaceuticals, Inc.
    • 13.15.1 Company Snapshot
    • 13.15.2 Company Overview
    • 13.15.3 Product Benchmarking
  • 13.16 iCo Therapeutics Inc.
    • 13.16.1 Company Snapshot
    • 13.16.2 Company Overview
    • 13.16.3 Product Benchmarking
  • 13.17 Roche Holding AG
    • 13.17.1 Company Snapshot
    • 13.17.2 Company Overview
    • 13.17.3 Financial Analysis
      • 13.17.3.1 Net Revenue, 2017-2022
      • 13.17.3.2 R&D, 2017-2022
    • 13.17.4 Product Benchmarking

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players